HHHiroki Higashihara

Hiroki Higashihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroki Higashihara has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spontaneous Thrombosis of a Long-Segment Hepatic Artery Aneurysm During Conservative Management: A Case Report on an 11-Year Follow-Up

    by Hiroki Higashihara, Hiroki Satomura, Takayasu Yamamoto, Yasushi Kimura, Kaishu Tanaka, Yusuke Ono, Noriyuki Tomiyama

    Hepatic artery aneurysms (HAAs) can rupture, yet the management of small, asymptomatic, long-segment lesions remains controversial. We report a 64-year-old man with an incidentally detected, long-segment aneurysmal change extending from the proximal common hepatic artery to the distal proper hepatic artery (approximately 80 mm). CT showed irregular, multilobulated ectasia with a focal saccular component (17 mm), an intimal flap, and mural thrombus, suggesting aneurysmal degeneration after dissection; a subtle dissection-like change was also suspected in the celiac trunk. Given the small maximal diameter, absence of symptoms, and concern for hepatic/biliary ischemia with intervention, close imaging surveillance was chosen. Progressive thrombosis led to complete occlusion at 5.5 years, with preserved hepatic enhancement and a more prominent left-gastric-right gastric collateral pathway. The aneurysm remained stably thrombosed without ischemic complications over 11 years. This case highlights that carefully selected, asymptomatic, anatomically complex HAAs may be managed conservatively with strict long-term follow-up.

  • Open Access

    Efficacy of modified technique for 1 cm core needle biopsy using a 2 cm cutting length with coaxial introducer needle

    by Hiroki Satomura, Yasushi Kimura, Masahisa Nakamura, Kosuke Tomotake, Koki Yamamoto, Kaishu Tanaka, Yusuke Ono, Hiroki Higashihara, Noriyuki Tomiyama

    Purpose: This study evaluated the efficacy of a modified core needle biopsy using a 2 cm stroke length to improve tissue yield for molecular analyses in cancer genomics medicine. Methods: In vitro biopsy weight evaluations were performed using agarose gels of varying hardness. Ex vivo biopsy weight evaluations were conducted using chicken liver, gizzard, breast, and pork loin tissues. Furthermore, in vivo experiments were performed using murine subcutaneous tumor models. The modified method involved using a coaxial introducer needle to maintain a 1 cm notch length while employing a 2 cm stroke length to increase tissue yield. Biopsy performance parameters, including sample weight and DNA yield, were compared between the modified and conventional methods. The firing speed of the biopsy needles with 1 cm and 2 cm stroke lengths was also measured using a high-speed camera. Results: The modified technique significantly increased the sample volume across all agarose gel concentrations (9.5–13% increase, P < 0.05). Ex vivo tests revealed significantly higher tissue yields in most samples, except for chicken gizzards. In vivo, the modified method produced significantly larger tissue samples (4.6 mg vs. 2.9 mg, P < 0.001) and higher DNA yield (8.2 ng vs. 6.9 ng, P < 0.05). In addition, the biopsy needle’s firing speed was 1.4–1.8 times faster with the 2 cm stroke length than 1 cm stroke. Conclusion: The modified biopsy technique using a 2 cm stroke length significantly improved tissue yield, enhancing the quality of biopsy samples for molecular analyses in precision medicine.


  • Open Access

    Effective Utilization of Conventional Transarterial Chemoembolization and Drug-eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma: A Guide to Proper Usage

    by Hiroki Higashihara, Yasushi Kimura, Yusuke Ono, Kaishu Tanaka, Noriyuki Tomiyama

    Transarterial chemoembolization is still an effective treatment option for hepatocellular carcinoma worldwide and is categorized into conventional transarterial chemoembolization with ethiodized oil transarterial chemoembolization and transarterial chemoembolization with drug-eluting spherical material transarterial chemoembolization. Several randomized controlled trials conducted in Europe have shown the equivalent efficacy of ethiodized oil transarterial chemoembolization and drug-eluting spherical material transarterial chemoembolization. However, a recent randomized controlled trials in Japan established the superiority of ethiodized oil transarterial chemoembolization in terms of complete response rates although higher liver toxicity for ethiodized oil transarterial chemoembolization. Nevertheless, the survival advantage of ethiodized oil transarterial chemoembolization is yet to be substantiated. The adverse effects of drug-eluting spherical material transarterial chemoembolization are milder than those of ethiodized oil transarterial chemoembolization, rendering drug-eluting spherical material transarterial chemoembolization an advantageous option for patients with bilobar tumors and impaired liver function/performance status. This article aims to provide an overview of these embolization techniques and a review of recent literature.


  • Open Access

    Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results

    by Eiji Kashiwagi, Yusuke Ono, Hiroki Yano, Shinya Kosai, Keisuke Nagai, Kaishu Tanaka, Hiroki Higashihara, Noriyuki Tomiyama

    Background: Lymphoceles can result from disruption of lymphatic vessels after surgical procedures in areas with extensive lymphatic networks. Percutaneous catheter drainage with sclerotherapy can be performed for the treatment of lymphoceles. OK-432 has been used to treat benign cysts, such as lymphangioma and ranula. Therefore, we aimed to report the efficacy and safety of sclerotherapy using OK-432 for postoperative lymphoceles. This study retrospectively analyzed 16 patients who underwent sclerotherapy using OK-432 for postoperative pelvic and para-aortic lymphoceles between April 1, 2012, and March 31, 2020. All the patients underwent percutaneous drainage before sclerotherapy. The indications for sclerotherapy were persistent drainage tube output of greater than 50 mL per day and recurrent lymphoceles after percutaneous drainage. If less than 20 mL per day was drained after sclerotherapy, the tube was removed. When the drainage tube output did not decrease to less than 20 mL per day after the first sclerotherapy, the second sclerotherapy was performed 1 week later. Technical success was defined as the completion of drainage and sclerotherapy procedures. Clinical success was defined as the resolution of the patient’s symptoms resulting from lymphoceles without surgical intervention. This study also evaluated the complications of sclerotherapy and their progress after sclerotherapy. Results: The mean initial lymphocele size and drainage duration after sclerotherapy were 616 mL and 7.1 days, respectively. The technical success rate and clinical success rate were 100% and 93%, respectively. Thirteen patients were treated by one-session sclerotherapy and three patients were treated by two-session sclerotherapy. Minor complications (fever) were observed in eight patients (50%). A major complication (small bowel fistula) was observed in one patient (7%). No recurrence of lymphoceles was observed during the mean follow-up period of 17 months. Conclusion: Sclerotherapy with OK-432 is an effective therapeutic method for postoperative lymphoceles. Although most complications are minor, a small bowel fistula was observed in one patient.


  • Risk Factors Associated with Clinical Failure of Uterine Artery Embolization for Postpartum Hemorrhage

    by Shinya Kosai, Hiroki Higashihara, Hiroki Yano, Eiji Kashiwagi, Keisuke Nagai, Kaishu Tanaka, Yusuke Ono, Tatsuya Miyake, Noriyuki Tomiyama


  • [A Case of Successful Selective Arterial Embolization for Traumatic Priapism].

    by Masatoshi Konishi, Taigo Kato, Shinya Kosai, Hiroki Higashihara, Toyofumi Abe, Motohide Uemura, Hiroshi Kiuchi, Ryoichi Imamura, Shinichiro Fukuhara, Norio Nonomura

    The first-line treatment for arterial (traumatic) priapism is follow-up, but no recommended duration has been established. We report a case of traumatic priapism that did not improve after one year of follow-up and was cured by arterial embolization. The patient was a 21-year-old male with a urethral injury caused by traffic trauma, and a urethral catheter was placed under fluoroscopic guidance. Magnetic resonance imaging (T2-weighted image) showed a low-signal area in the right penile corpus cavernosum. The urethral catheter was removed 1 month after the injury, but the erection persisted, and the patient was referred to our department 8 months after the injury. Contrast-enhanced computed tomography (CT) revealed enhancement effect of the right penile corpus cavernosum, which was diagnosed as traumatic priapism, and selective arterial embolization was performed 1 year after the injury. Angiography revealed an extravascular leak from the right patent ductus arteriosus into the cavernous sinus of the penis, and a gelatin sponge (Serescue®︎) was injected as an embolization material into the distal portion of the right patent ductus arteriosus. Immediately after the operation, the penis became fully erect, but gradually softened. One month after embolization, priapism improved, and 6 months after embolization, contrast-enhanced CT confirmed the disappearance of the enhancement effect of the right corpus cavernosum. There has been no relapse of symptoms for 10 months after embolization. Selective arterial embolization for traumatic priapism is considered to be a useful treatment even after a certain period of follow-up.

  • Open Access

    PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibro-adipose vascular anomaly (FAVA)

    by Yumiko Hori, Katsutoshi Hirose, Michio Ozeki, Kenji Hata, Daisuke Motooka, Shinichiro Tahara, Takahiro Matsui, Masaharu Kohara, Hiroki Higashihara, Yusuke Ono, et al.

    Background: Fibro-adipose vascular anomaly (FAVA) is a rare and new entity of vascular anomaly. Activating mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene were identified at a frequency of 62.5% in FAVA cases. The PIK3CA mutations excessively activate mammalian target of rapamycin (mTOR) pathway, which promotes angiogenesis and lymphangiogenesis, implying that PIK3CA mutations may act as drivers of FAVAs. This study investigated the correlations between PIK3CA mutational status, clinicopathological features and immunohistochemical expression of the mTOR pathway in a series of FAVA. Methods: We retrospectively evaluated the clinical and pathological findings of four FAVA cases. We performed next-generation sequencing (NGS) with a custom panel of genes associated with the mTOR pathway and genes responsible for other vascular anomalies; followed by direct sequencing and immunohistochemical analysis of the mTOR pathway. Results: Two PIK3CA-mutation cases and two PIK3CA-wild-type (wt) cases exhibited similar typical clinical features of FAVA. Histological analysis revealed venous malformation, lymphatic malformation, nerves containing enlarged abnormal vessels and fibrofatty tissue were observed regardless of PIK3CA mutational status. In contrast to clinical and histological findings, the immunohistochemical expression of activated AKT and mTOR that are upstream of the mTOR pathway was detected in abnormal vessels of PIK3CA-mutation cases but not in those of PIK3CA-wt cases. However, activated eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1), both of which are downstream effectors of the mTOR pathway, were expressed in abnormal vessels of both PIK3CA-mutation and PIK3CA-wt cases. Furthermore, targeting NGS did not find any common genetic mutations involved in the mTOR pathway among PIK3CA-wt cases. Conclusions: There was no significant association between the presence of PIK3CA mutations and the clinicopathological features of FAVA, suggesting that the PIK3CA gene is not necessarily involved in the onset of FAVA. FAVAs lacking PIK3CA mutations may be caused by other gene mutations that activate 4EBP1 and S6K1.


  • Open Access

    Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan

    by Hiroki Higashihara, Yusuke Ono, Kaisyu Tanaka, Kosuke Tomotake, Noriyuki Tomiyama

    Hiroki Higashihara *, Yusuke Ono, Kaisyu Tanaka, Kosuke Tomotake, and Noriyuki Tomiyama. Int J Gastrointest Interv 2021;10:152-60. https://doi.org/10.18528/ijgii210042


  • Open Access

    The diagnostic value of dual-phase cone-beam CT during hepatic arteriography in transarterial chemoembolization for hepatocellular carcinoma

    by Hiroki Higashihara, Keigo Osuga, Hiromitsu Onishi, Atsushi Nakamoto, Takahiro Tsuboyama, Noriyuki Tomiyama

    To evaluate the diagnostic value of dual-phase cone beam CT during hepatic arteriography (CBCTHA) for hepatocellular carcinoma (HCC). Thirty seven patients with unresectable HCC underwent the dual-phase CBCTHA prior to transarterial chemoembolization (TACE). Three blinded observers independently reviewed and compared the first phase CBCTHA images alone and the dual phase CBCTHA images. Diagnostic accuracy was evaluated by the alternative free-response receiver operating characteristic method (Area under the curve: Az value). Sensitivities were analyzed with the paired t test. The analysis was performed for overall HCCs, HCCs up to 1 cm and those larger than 1 cm. For all HCCs and HCCs up to 1 cm, Az value and sensitivity showed no significant difference between the first-phase CBCTHA alone and the dual-phase CBCTHA (Az: 0.81 vs 0.88, P = .07, 0.79 and 0.85, P = .14, sensitivity: 0.61 and 0.73, P = .11, 0.41 and 0.52, P = .33, respectively). For HCCs larger than 1 cm, the mean Az value and sensitivity for the dual-phase CBCTHA were significantly higher than those for the first phase CBCTHA alone (Az: 0.96 vs 0.92, P = .008, sensitivity: 0.85 vs 0.75, P = .013, respectively). The diagnostic accuracy of the dual-phase CBCTHA was superior to that of the first phase CBCTHA alone in the diagnosis of HCC larger than 1 cm.


  • Open Access

    Initial experience with use of hydrogel microcoils in embolization of pulmonary arteriovenous malformations

    by Keigo Osuga, Kentaro Kishimoto, Kaishu Tanaka, Masahisa Nakamura, Yusuke Ono, Noboru Maeda, Hiroki Higashihara, Tetsuro Nakazawa, Noriyuki Tomiyama

    The purpose of this study is to describe our initial experience with embolization of pulmonary arteriovenous malformations (PAVMs) using hydrogel microcoils. The technical and radiological outcomes were retrospectively reviewed in seven patients with nine simple-type PAVMs (median feeder size 4 mm, range 3-6 mm) who underwent embolization. Hydrogel microcoils were mainly used, and detachable bare microcoils were combined as needed to occlude the terminal feeding artery just before the sac. Of a total of 43 microcoils, 30 (69.8%) hydrogel microcoils were deployed in eight PAVMs with the median number 3.5 (range 2 to 6) per lesion. All hydrogel microcoils were successfully deployed without microcatheter stuck or malposition. In the remaining one small PAVM, only soft bare microcoils were used, however, resulting in recanalization requiring additional coils in the second session. The venous sac was substantially shrunk in all lesions treated with hydrogel microcoils with the median size reduction rate 95.0% (range 81.8% to 99.0%) during the median follow-up period 10 months (range 6 to 18 months). In conclusion, hydrogel microcoils were safely and effectively applied for occluding PAVMs with relatively small feeders.